Key result
Combined topical and oral Minoxicapil increases total hair count by ~12 hairs versus spray alone.
Why the study?
Minoxidil topical and finasteride oral treatments for androgenetic alopecia have local and systemic adverse effects, prompting evaluation of combination therapies for improved outcomes.
Does combined topical and oral therapy containing oleanolic acid, apigenin, and biotinyl tripeptide-1 improve trichoscopic parameters compared to topical monotherapy in patients with androgenetic alopecia?
RCT (n=48)
Open-label
1:1 ratio
No
Does combined topical and oral therapy containing oleanolic acid, apigenin, and biotinyl tripeptide-1 improve trichoscopic parameters compared to topical monotherapy in patients with androgenetic alopecia?
Combination of topical and oral therapy containing oleanolic acid, apigenin, and biotinyl tripeptide-1 provides greater trichologic improvements than topical therapy alone in patients with androgenetic alopecia.
Answers are grounded in this paper and cite their sources.
May support adjunctive oral therapy in androgenetic alopecia; leaves open need for RCTs to confirm efficacy and safety.
Background: Androgenetic alopecia (AGA) is a prevalent condition characterized by progressive follicular miniaturization. Minoxidil topical treatment and finasteride oral treatment are the golden standard, but they are limited by local and systemic adverse effects. Combination therapies targeting both follicular stimulation and nutritional support may enhance clinical outcomes. Objective: To evaluate the efficacy of a combined topical and oral therapy compared to topical monotherapy in patients with AGA using trichoscopic and clinical parameters. Methods: In this open-label, prospective trial, 48 patients were assigned to receive either a topical spray alone (Group A) or in combination with oral capsules (Group B) for 3 months. Trichoscopic parameters were assessed at baseline and post-treatment. Paired and independent t-tests, along with Cohen’s d effect sizes, were used to evaluate intra- and inter-group changes. Results: Both groups demonstrated improvements in hair density, thickness, and anagen/telogen ratio. Group B exhibited significantly greater increases in total hair count and anagen conversion (p < 0.05). The effect sizes ranged from small to large, with the most pronounced changes observed in anagen/telogen ratio (Cohen’s d = 0.841) in males. Conclusions: The combination of topical and oral treatment led to greater trichologic improvements than topical therapy alone. While extrapolated projections at 6 and 12 months suggest continued benefit, future studies with longer duration and placebo controls are required to validate these findings.
No takes yet. Share an insight, caveat, or question.
Voiculescu et al. (2025) conducted an RCT in Androgenetic alopecia (n=48). Minoxicapil topical spray and oral capsules vs. Minoxicapil topical spray alone was evaluated on Change in total hair count at 3 months (MD 11.8, p=0.039). The combination of topical Minoxicapil spray and oral capsules significantly increased total hair count by a mean difference of 11.8 hairs compared to topical spray alone after 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: